Healthmap Taps Veteran CMO to Reshape the Future of Kidney Care

TAMPA, Fla. – May 13, 2026 – Healthmap Solutions, a leading kidney population health management company, has appointed Dr. Jonathan Gavras as its new Chief Medical Officer, a move signaling a major push to deepen its clinical strategy and accelerate innovation in a rapidly evolving healthcare sector.

Dr. Gavras, a board-certified physician with an extensive career as a healthcare executive, is no stranger to the company. He transitions from a five-year tenure on Healthmap’s Board of Directors to this executive leadership role, bringing a deep, intrinsic understanding of the organization's mission and operational framework. The appointment places a proven clinical and business leader at the helm of a company navigating the complex and costly landscape of chronic kidney disease (CKD) and end-stage renal disease (ESRD).

A Strategic Appointment with Deep Roots

The decision to bring Dr. Gavras into the C-suite is being framed as a deliberate, strategic enhancement of Healthmap's capabilities. His background includes high-profile CMO roles at Florida Blue and Prime Therapeutics, along with senior leadership positions at industry giants like UnitedHealth Group and Prudential Healthcare. This experience provides him with a panoramic view of the payer, provider, and health services ecosystem.

“Dr. Gavras is a longstanding member of our Board of Directors, and we are thrilled to have him lend his clinical expertise and leadership to us as Chief Medical Officer,” said Eric Reimer, Healthmap Chief Executive Officer. “I have worked with Dr. Gavras in various capacities over the past 30 years, and he is widely known to be among the best clinical minds when it comes to reducing medical costs while improving outcomes.”

Reimer’s confidence underscores the dual mandate facing modern healthcare leaders: enhancing patient care while bending the cost curve. In his new role, Dr. Gavras is tasked with leading Healthmap’s clinical strategy and strengthening partnerships with health plans and providers—a mission that aligns perfectly with his track record.

“I’m confident that his experience will further enhance Healthmap’s ability to deliver a high-quality clinical program to our clients, providers, and members,” Reimer added.

Reshaping Kidney Care from the Inside Out

Dr. Gavras joins a company that has already established itself as a disruptor in kidney care. Healthmap’s model is built on an “upstream” approach, focusing on identifying and managing patients in the earlier stages of CKD (stages 3 and 4) to slow disease progression and manage comorbidities like diabetes and hypertension. The goal is to prevent or delay the onset of ESRD, a condition that is devastating for patients and incredibly costly for the healthcare system, with renal replacement therapy averaging $90,000 per patient annually.

The results of this strategy have been significant. The NCQA-accredited company reports that its Kidney Health Management (KHM) program achieves a 10-15% reduction in total medical expenses for its managed populations. It also boasts impressive member engagement rates exceeding 70%. Perhaps most critically, Healthmap has achieved a 30-40% home dialysis usage rate among its members, a figure that dramatically outpaces the national average of just 12%. This shift is a key goal of federal policy, as it offers patients greater flexibility and quality of life.

Furthermore, the company's data shows a 50% reduction in “dialysis crash” incidents—where patients start dialysis in an emergency setting—and a 20-30% reduction in hospital admissions and readmissions. Dr. Gavras's leadership is expected to build on this foundation, driving further clinical advancements and refining the care model for the approximately 160,000 members Healthmap serves across 43 states and Puerto Rico.

The Private Equity and Market Context

This leadership change also occurs within a broader context of strategic investment and market transformation. Dr. Gavras has served as an Operating Partner with WindRose Health Investors since October 2023. WindRose, a New York-based private equity firm, led an $85 million equity recapitalization of Healthmap in 2019, providing the capital to fuel its national expansion. The placement of a WindRose operating partner in a key leadership role at a portfolio company highlights a hands-on approach to value creation, leveraging executive expertise to drive growth and operational excellence.

The appointment is also timely. The kidney care landscape is being reshaped by powerful forces, including new payment models from the Centers for Medicare & Medicaid Services (CMS). Initiatives like the ESRD Treatment Choices (ETC) and Kidney Care Choices (KCC) models are designed to incentivize home dialysis, increase kidney transplantation, and shift the industry toward value-based arrangements that reward better outcomes and lower costs. With his deep experience in cost management and clinical improvement, Dr. Gavras is uniquely positioned to help Healthmap and its partners navigate this new paradigm.

A Future Built on Data and Digital Health

At the core of Healthmap's strategy is its proprietary technology platform, “Compass,” which uses predictive analytics and AI to identify high-risk patients and guide personalized care interventions. The company is doubling down on this technological edge, having recently acquired Carium, a digital care management and communication platform, to enhance patient engagement and virtual care capabilities.

This focus on technology aligns with wider industry trends, including the development of portable and wearable dialysis devices and the use of AI to predict disease progression. As the global CKD market is projected to grow from $52.9 billion in 2025 to $82.6 billion by 2030, technology-driven, preventative care models like Healthmap's are poised for significant growth.

In a statement, Dr. Gavras expressed his enthusiasm for the path ahead. “Healthmap has built a strong foundation in managing complex patient populations and delivering improved outcomes,” he said. “I’m honored to take on this new role in supporting the organization’s continued advancements in clinical excellence.” With a seasoned leader, a proven model, and a clear focus on innovation, Healthmap appears well-equipped to not only manage the challenges of kidney disease but to fundamentally change how it is treated for millions of Americans.